Drugs / CoVLP
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04450004 | Jul → Sep 2020 | COVID-19 | Medicago | Completed | No outcome recorded |
| Phase 2/31 trial · 1 met primary | ||||||
| Phase 2/3 | NCT04636697 | Nov 2020 → Aug 2021 overdue | COVID-19 | Medicago | Active not recruiting | Met primary |
| Phase 31 trial | ||||||
| Phase 3 | NCT05040789 | Nov 2021 → May 2022 | COVID-19 | Medicago | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CoVLP | “Coronavirus-like particles (CoVLP) that are produced in plants and display the prefusion spike glycoprotein of the original strain of severe acute respiratory syndrome...” PMID 35507508 ↗ May 20222“Here we report Day 42 interim safety and immunogenicity data from an observer-blinded, dose escalation, randomized controlled study of a virus-like particle vaccine candidate...” PMID 34007070 ↗ May 2021 |
| Modality | Vaccine | “virus-like particle vaccine candidate produced in plants” PMID 34007070 ↗ May 2021 |
| Route | Intramuscular | “Subjects will receive two intramuscular (IM) injections 21 days apart (Day 0 and Day 21), into the deltoid region of the alternating arm (each arm will be injected once), with...” NCT04450004 ↗ |